NCT03947723

Brief Summary

Trichiasis is a disorder of misdirected eyelashes in which the lashes grow inward towards the eye. Trichiasis can occur as a result of chronic inflammation, infection, such as in herpes or trachoma, trauma, or rare diseases like ocular cicatricial pemphigoid or Stevens-Johnson syndrome. Trichiasis can result significant pain and corneal compromise, ranging from punctate erosions to frank abrasions, as the lashes constantly contact and irritate the ocular surface. Several treatment modalities are available, including mechanical epilation, electroepilation, cryotherapy, laser therapy, and surgical procedures to redirect the lashes. Radiofrequency ablation is a type of electroepilation that utilizes radiowaves to heat and destroy hair follicles. A fine needle is inserted into the follicle and current is applied to destroy the follicle. The needle allows the energy to be focused into the follicle and limits scarring of the surrounding tissues, and the follicles are in theory permanently destroyed in this procedure. Success rates are variable however, ranging from 56 to 90%. Currently, there is no standardized protocol for performing radiofrequency ablation. Many practitioners choose their power settings based on experience, and the Ellman Surgitron machine, a commonly used radiofrequency unit, actually states in their instructions that the power should be titrated based on user experience. In the literature, settings anywhere from 1 to 3 are seen. In this study, our purpose is to examine the effects of different power settings in radiofrequency at the histologic level. The investigators plan to test different power settings on eyelid tissue that would be normally excised and discarded during eyelid correction surgeries. The investigators hope to determine if there is an ideal power setting to achieve hair follicle destruction while minimizing surrounding tissue damage, which could then be used as the standard power setting for radiofrequency ablation of trichiatic lashes in clinical practice. The investigators hypothesize that as power increases, the extent and severity of tissue damage will increase.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2019

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 7, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 13, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

July 2, 2019

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 22, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 22, 2020

Completed
Last Updated

April 25, 2023

Status Verified

April 1, 2023

Enrollment Period

12 months

First QC Date

May 7, 2019

Last Update Submit

April 21, 2023

Conditions

Keywords

trichiasisradiofrequency ablationepilationhistology

Outcome Measures

Primary Outcomes (2)

  • Extent of tissue damage

    The extent of damage will be measured on the tissue sections. The diameter of abnormal/damaged tissue will be measured in microns.

    Through study completion, approximately 6 months

  • Severity of tissue damage

    The severity will be graded on a scale from 0 to 3, with 0 being no tissue changes and going up to 3 which will represent severe tissue changes.

    Through study completion, approximately 6 months

Study Arms (4)

Low power

EXPERIMENTAL

These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of "low."

Device: Radiofrequency ablation

1 power

EXPERIMENTAL

These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.

Device: Radiofrequency ablation

1.5 power

EXPERIMENTAL

These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.5

Device: Radiofrequency ablation

2 power

EXPERIMENTAL

These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 2.

Device: Radiofrequency ablation

Interventions

The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.

1 power1.5 power2 powerLow power

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Undergoing the bilateral tarsal strip procedure
  • The procedure requires at least 5 mm of tissue to be excised from each side to provide adequate tightening of the lower eyelids (to be determined intra-operatively)
  • Caucasian (to control for any different responses ellicited by the treatment in pigmented skin)

You may not qualify if:

  • previous treatments for trichiasis along the lateral lower eyelid
  • madarosis of eyelashes
  • hypertrichosis of eyelashes
  • patients undergoing only unilateral tarsal strip procedures
  • history of eyelid trauma or chemical burns
  • patients with a history of disorders affecting the mucus membranes (ie: Stevens-Johnson syndrome, ocular cicatricial pemphigoid)
  • history of eyelid surgery
  • history of facial skin cancers
  • patients with eyelid lesions affecting the lateral lower eyelids
  • patients with active inflammatory ocular diseases (keratitis, scleritis, conjunctivitis, etc).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (3)

  • Nakamoto, D., Bernardino, C.R. The Annoying Lash in the Eye: A Review of Trichiasis. Review of Ophthalmology. Retrieved from: https://www.reviewofophthalmology.com/article/the-annoying-lash-in-the-eye-a-review-of-trichiasis. 2007.

    BACKGROUND
  • Kim GN, Yoo WS, Kim SJ, Han YS, Chung IY, Park JM, Yoo JM, Seo SW. The effect of 0.02% mitomycin C injection into the hair follicle with radiofrequency ablation in trichiasis patients. Korean J Ophthalmol. 2014 Feb;28(1):12-8. doi: 10.3341/kjo.2014.28.1.12. Epub 2014 Jan 21.

    PMID: 24505196BACKGROUND
  • Kezirian GM. Treatment of localized trichiasis with radiosurgery. Ophthalmic Plast Reconstr Surg. 1993 Dec;9(4):260-6. doi: 10.1097/00002341-199312000-00006.

    PMID: 8305373BACKGROUND

MeSH Terms

Conditions

Trichiasis

Interventions

Radiofrequency Ablation

Condition Hierarchy (Ancestors)

Eyelid DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Radiofrequency TherapyTherapeuticsAblation TechniquesSurgical Procedures, Operative

Study Officials

  • Priya Sahu, MD

    Ochsner Health System

    PRINCIPAL INVESTIGATOR
  • Jayne Weiss, MD

    Louisiana State University Health Sciences Center

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The person examining the slides will be blinded to the power setting used.
Purpose
OTHER
Intervention Model
FACTORIAL
Model Details: This will be a modified factorial trial. The tissue from all patients will be divided into 4 sections and undergo radiofrequency ablation at different settings in each section, giving us 4 groups. These 4 groups will be compared to each other.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 7, 2019

First Posted

May 13, 2019

Study Start

July 2, 2019

Primary Completion

June 22, 2020

Study Completion

June 22, 2020

Last Updated

April 25, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will not share

No plan to share with other researchers